The current perspective and opportunities of small nucleic acid‐based therapeutics
Drug Development Research · 2024-04 · 85 (2)
DOI: 10.1002/ddr.22164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 27.02.2024. Verfasst von Yang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, Third Military Medical Universit…. Hauptthemen laut MEDLINE: Nucleic Acids, Neoplasms, Metabolic Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Major project of Study on Pathogenesis and Epidemic Prevention Technology System, Ministry of Science and Technology of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Compared to traditional small molecule and antibody drugs, RNA‐based drugs offer a simple design, short research and development cycles, high specificity, broad treatment fields, and long‐term efficacy. As a result, RNA‐based drugs are extensively used to treat genetic diseases, tumors, viral infections, and other illnesses, suggesting that they have the potential to become the third‐largest drug class after small molecule and antibody drugs. Currently, more than 10 small nucleic acid drugs have gained regulatory approval. The commercialization successes of small nucleic acid drugs will stimulate the development of RNA‐based drugs. Small nucleic acid drugs primarily target liver diseases, metabolic diseases, genetic diseases, and tumors, and there is also significant potential for expanding indications in the future. This review provides a brief overview of the advantages and development of small nucleic acid‐based therapeutics and shows a focus on platform technologies such as chemical modifications and delivery systems that have enabled the clinical translation of small nucleic acid‐based therapeutics. Additionally, we summarize the latest clinical progress in small nucleic acid‐based therapeutics for the treatment of various diseases, including rare diseases, liver diseases, metabolic diseases, and tumors. Finally, we highlight the future prospects for this promising treatment approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, Third Military Medical University, Chongqing, China.
- Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, China.
- Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing, China.
- Department of Pediatrics, Ludwig-Maximilians University of Munich, Munich, Germany.
ORCID-Profile: Qin Xiao
Förderung
- Major project of Study on Pathogenesis and Epidemic Prevention Technology System
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Talents: Exceptional Young Talents Project
Zitieren
APA
Chen, Y., Li, Y., Li, C., Zhang, D., Liu, Y., Zhang, J., Guan, S., Ding, X., & Xiao, Q. (2024). The current perspective and opportunities of small nucleic acid‐based therapeutics. Drug Development Research, 85(2). https://doi.org/10.1002/ddr.22164
Vancouver
Chen Y, Li Y, Li C, Zhang D, Liu Y, Zhang J, et al. The current perspective and opportunities of small nucleic acid‐based therapeutics. Drug Development Research. 2024;85(2). doi:10.1002/ddr.22164
BibTeX
@article{Chen2024,
author = {Chen, Yang and Li, Yang and Li, Chao and Zhang, Dandan and Liu, Yuheng and Zhang, Jingjing and Guan, Shan and Ding, Xiaoyan and Xiao, Qin},
title = {The current perspective and opportunities of small nucleic acid‐based therapeutics},
journal = {Drug Development Research},
year = {2024},
volume = {85},
number = {2},
doi = {10.1002/ddr.22164}
}
EUVIMED